Evidence map›Paper›PMID 39896571›Full record

ArticlebioRxiv : the preprint server for biology2025

A Robust Proteomics-Based Method for Identifying Preferred Protein Targets of Synthetic Glycosaminoglycan Mimetics.

Daniel K Afosah, Ravikumar Ongolu, Rawan M Fayyad, Adam Hawkridge, Umesh R Desai

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Daniel K AfosahDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298.
Ravikumar OngoluDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298.
Rawan M FayyadDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298.
Adam HawkridgeDepartment of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298.
Umesh R DesaiDepartment of Medicinal Chemistry, School of Pharmacy, Virginia Commonwealth University, Richmond, VA 23298.ORCID 0000-0002-1976-6597

Funding

Therapeutic assessment of synthetic heparin sulfates in transplantation modelsP01HL107152 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DESAI, UMESH RAMANLAL · 2011 to 2017
$15.8M
Project 3: Role of Glycosaminoglycans in HematopoiesisP01HL151333 · NHLBI · VERSITI WISCONSIN, INC. · PI HOFFMEISTER, KARIN MARIA · 2021 to 2025
$12.3M
Glycans in Blood Homeostasis and DiseaseK12HL141954 · NHLBI · VERSITI WISCONSIN, INC. · PI DAHMS, NANCY M., DESAI, UMESH RAMANLAL · 2018 to 2022
$4.9M
Tool for Predicting Glycosaminoglycan Recognition of ProteinsU01CA241951 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DESAI, UMESH RAMANLAL · 2019 to 2021
$991k
Synthetic glycosaminoglycan mimetics as regulators of megakaryopoiesis and thrombopoiesisR00HL161423 · NHLBI · UNIVERSITY OF NORTH TEXAS · PI Daniel Kwame Afosah · 2024 to 2026
$683k
Synthetic glycosaminoglycan mimetics as regulators of megakaryopoiesis and thrombopoiesisK99HL161423 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI AFOSAH, DANIEL KWAME · 2022 to 2023
$359k
NCI NIH HHS U01 CA241951NHLBI NIH HHS K12 HL141954NHLBI NIH HHS K99 HL161423NHLBI NIH HHS P01 HL107152NHLBI NIH HHS P01 HL151333NHLBI NIH HHS R00 HL161423
6 · The paper itself

Abstract

A robust technology is critically needed for identifying preferred protein targets of glycosaminoglycans (GAGs), and synthetic mimetics thereof, in biological milieu. We present a robust 10-step strategy for identification and validation of preferred protein targets of highly sulfated, synthetic, small, GAG-like molecules using diazirine-based photoaffinity labeling-proteomics approach. Our work reveals that optimally designed, homogeneous probes based on minimalistic photoactivation and affinity pulldown groups coupled with rigorous proteomics, biochemical and orthogonal validation steps offer excellent potential to identify preferred targets of GAG mimetics from the potentially numerous possible targets that cloud GAG interaction studies. Application of this 10-step strategy for a promising highly sulfated, small GAG mimetic led to identification of only a handful of preferred targets in human plasma. This new robust strategy will greatly aid drug discovery and development efforts involving GAG sequences, or sulfated small mimetics thereof, as leads.

Indexed as

glycosaminoglycan-binding proteinsglycosaminoglycansinteractomephotoaffinityproteomics

Identifiers

PMID39896571
PMCPMC11785238

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.